1-11 of 11
Dinara Makenbaeva, MD, MBA
Close
Sort by
Journal Articles

Prevalence of Comorbidities Relevant to the Choice of Second-Generation (2-G) Tyrosine Kinase Inhibitor (TKI) for the Treatment of Chronic Myeloid Leukemia (CML) in the United States Using Real-World Claims Databases

Elias J. Jabbour, MD, Min You, MS, Trong Kim Le, MPH, MS, John Brokars, MS, Alexander Brun, PharmD, Dinara Makenbaeva, MD MBA
Journal: Blood
Blood (2018) 132 (Supplement 1): 4265.
https://doi.org/10.1182/blood-2018-99-113568
Published: 2018
Journal Articles

Realized and Projected Cost Savings from the Introduction of Generic Imatinib, with Minimal Additional Savings to Payers through Formulary Management

Lisa Bloudek, John Brokars, MS, Campbell David, PharmD, MS, Dinara Makenbaeva, MD MBA
Journal: Blood
Blood (2018) 132 (Supplement 1): 3533.
https://doi.org/10.1182/blood-2018-99-111966
Published: 2018
Journal Articles

The Impact of Chronic Myeloid Leukemia Therapy Management on the Oncology Care Model

Elias J. Jabbour, MD, Martin F Mendiola, MD MPH, Melissa Lingohr-Smith, PhD, Brandy Menges, PhD, Jay Lin, PhD MBA, Dinara Makenbaeva, MD MBA
Journal: Blood
Blood (2018) 132 (Supplement 1): 2265.
https://doi.org/10.1182/blood-2018-99-112484
Published: 2018
Journal Articles

Economic Modeling of the Potential Impact of Chronic Myeloid Leukemia (CML) Monitoring on Healthcare Costs

Elias J. Jabbour, MD, Lisa Siegartel, MPH, Jay Lin, PhD MBA, Melissa Lingohr-Smith, PhD, Brandy Menges, PhD, Dinara Makenbaeva, MD MBA
Journal: Blood
Blood (2017) 130 (Supplement 1): 3378.
https://doi.org/10.1182/blood.V130.Suppl_1.3378.3378
Published: 2017
Journal Articles

Impact of Earlier Vs. Later Monitoring on Disease Progression and Economic Outcomes Among Patients with Chronic Myeloid Leukemia in the Real-World Setting

Elias J. Jabbour, MD, Lisa Siegartel, MPH, Jay Lin, PhD MBA, Melissa Lingohr-Smith, PhD, Brandy Menges, PhD, Dinara Makenbaeva, MD MBA
Journal: Blood
Blood (2017) 130 (Supplement 1): 2175.
https://doi.org/10.1182/blood.V130.Suppl_1.2175.2175
Published: 2017
Journal Articles

Evaluation of Healthcare Resource Utilization and Costs Among Patients with Chronic Myeloid Leukemia after Disease Progression

Elias Jabbour, MD, Jay Lin, PhD MBA, Lisa R Siegartel, MPH, Melissa Lingohr-Smith, PhD, Brandy Menges, PhD, Dinara Makenbaeva, MD MBA
Journal: Blood
Blood (2016) 128 (22): 3573.
https://doi.org/10.1182/blood.V128.22.3573.3573
Published: 2016
Journal Articles

Incidence of Type II Diabetes Mellitus and Hyperlipidemia in Patients Prescribed Dasatinib or Nilotinib As First or Second Line Therapy for Chronic Myelogenous Leukemia (CML)

Meg Franklin, PharmD, PhD, Leah Burns, MPH, Samuel Perez, BA, Deepak Yerragolam, B. Tech, Dinara Makenbaeva, MD MBA
Journal: Blood
Blood (2016) 128 (22): 4766.
https://doi.org/10.1182/blood.V128.22.4766.4766
Published: 2016
Journal Articles

Evaluation of Cardiovascular Disease Risk in Chronic Myelogenous Leukemia Patients Using Electronic Medical Records from Community-Based Oncology Practices in the United States

Anna O. D'Souza, B.Pharm, PhD, Dinara Makenbaeva, MD MBA, Eileen Farrelly, MPH, Pamela Landsman-Blumberg, MPH, DrPH, Bjorn Bolinder, MSc,MBA
Journal: Blood
Blood (2015) 126 (23): 4478.
https://doi.org/10.1182/blood.V126.23.4478.4478
Published: 2015
Journal Articles

Evaluation of Comorbidities Relevant to Tyrosine Kinase Inhibitor Treatment Among Patients with Chronic Myelogenous Leukemia in the U.S. Managed Care Setting

Elias Jabbour, MD, Dinara Makenbaeva, MD MBA, Melissa Lingohr-Smith, PhD, Jay Lin, PhD MBA
Journal: Blood
Blood (2014) 124 (21): 4550.
https://doi.org/10.1182/blood.V124.21.4550.4550
Published: 2014
Journal Articles

Cost-Effectiveness Analysis (CEA) of Sequential Treatment with Tyrosine Kinase Inhibitors (TKIs) for Chronic Myelogenous Leukemia (CML)

John Whalen, BS, Ipek Stillman, MS, Apoorva Ambavane, MPH, Eugene Felber, PhD MSPH, Dinara Makenbaeva, MD MBA, Bjorn Bolinder, MBA
Journal: Blood
Blood (2014) 124 (21): 2607.
https://doi.org/10.1182/blood.V124.21.2607.2607
Published: 2014
Journal Articles

Type of Bleeding Among Patients with Nonvalvular Atrial Fibrillation in a Large Managed Care Population

Steven Deitelzweig, MD, Brett Pinsky, MPH, Erin Buysman, MS, Michael Lacey, MSc, Dinara Makenbaeva, MD, MBA, Daniel Wiederkehr, John Graham, PharmD
Journal: Blood
Blood (2012) 120 (21): 2073.
https://doi.org/10.1182/blood.V120.21.2073.2073
Published: 2012